You searched for "ESCRS"
See sweet to C-suite: Imran Rahman
See also - See sweet to C-suite: Peter Holland In this three-part conversation series, Co-editor David Lockington speaks with highly influential individuals about their journey to the top, with advice for the next generation of leaders. Part Two: David speaks...
Insights in resistant diabetic macular oedema
5 August 2022
| Sofia Rokerya
|
EYE - Vitreo-Retinal
This article gives a bird’s eye review of the different modalities for the treatment of diabetic macular oedema (DME). The debut of anti-VEGFs has brought a paradigm shift in DME management. This treatment has now become a major breakthrough in...
Dr Glaucomflecken: Stayin’ Alive
13 October 2022
| Peter Cackett
|
EYE - General
Peter Cackett spoke to ophthalmologist and social media sensation Dr Glaucomflecken about his early days in comedy, the role satire can play in impacting medical governance, and where he might take his brand of medical comedy next. It was towards...
Post hoc analysis of the CANTREAT randomised trial
1 December 2023
| Sofia Rokerya
|
EYE - Vitreo-Retinal
|
Age-related macular degeneration, Randomized clinical trial, Ranibizumab, Treat-and-extend
CANTREAT, a Canadian multicentre two-year randomised trial compares treat and extend treatment (T&E) relative to the monthly administration of Ranibizumab in nAMD. Two-hundred and eighty-five treatment-naïve patients with nAMD were randomised to receive either a once-monthly dosing or T&E regimen...
Long-term outcomes of intravitreal ranibizumab for neovascular AMD
This is a single centre prospective study for the long-term, whole population ‘real-world’ clinical outcomes of ranibizumab therapy in treatment-naïve patients for neovascular age-related macular degeneration (AMD). This study recorded: demographics, Early Treatment Diabetic Retinopathy Study visual acuity (ETDRS VA)...
Results of fixed aflibercept treatment regime in type 3 neovascularisation
1 April 2020
| Sofia Rokerya
|
EYE - Vitreo-Retinal
In this prospective study the authors evaluate the effect of intravitreal aflibercept injections in the treatment of naive type 3 neovascularisation using a fixed treatment regime. Fourteen eyes of 14 patients were studied. All patients were treated with intravitreal 2.0...
Verteporfin shortage: treatment options and outcomes in chronic non-resolving central serous chorioretinopathy
4 February 2025
| Sofia Rokerya
|
EYE - Vitreo-Retinal
Half-dose photodynamic therapy (HD-PDT) with verteporfin has been the therapy of choice in non-resolving central serous chorioretinopathy lasting longer than four months. Since 2021, a worldwide shortage of verteporfin due to manufacturing issues prompted adjustments in treatment practices. This retrospective,...
Treatment of diabetic macular oedema
1 June 2014
| Samantha S Mann
|
EYE - Vitreo-Retinal
Diabetic macular oedema (DMO) is a common complication associated with diabetic retinopathy, and the most common cause of visual impairment in diabetes [1]. With predicted rising levels of diabetes (in England by 2025 the estimated population with diabetes will be...
Prostaglandin associated periorbitopathy
Prostaglandins are known to cause periorbital adverse effects. The aim of this retrospective case series was to compare the frequency of prostaglandin associated periorbitopathy (PAP) between bimatoprost, latanoprost and travoprost users. Five PAP findings were evaluated: upper lid ptosis, deepening...The results of the last survey Jun23
5 June 2023
| Amar Alwitry
|
EYE - General
*Please be aware that this data does not form part of a peer reviewed research study. The information therein should not be relied upon for clinical purposes but instead used as a guide for clinical practice and reflection. I continue...
Binocular summation responses in strabismic amblyopia
A preliminary study was conducted to determine whether binocular summation (BS) in strabismic amblyopia is more decreased than in strabismus alone and whether strabismus surgery improves BS. The study included 15 strabismic amblyopes, 30 normal controls and 30 strabismic controls....
Avastin vs. Volon A for diabetic macular oedema
1 June 2014
| Nana Theodorou
|
EYE - Vitreo-Retinal
This prospective randomised interventional clinical trial compared 30 diabetic patients with macular oedema treated with either intravitreal injections of bevacizumab (Avastin) or triamcinolone (Volon A). One group initially received three injections of 2.5 mg Avastin in monthly intervals whilst the...
